中国生物制药(01177)今日盘中大涨5.19%，引起了市场的广泛关注。
消息面上，国家医保局近日公示了通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单，本次形式审查呈现申报品种数量提高、通过率大幅提升、申报品种以新药为主等特征，充分体现了医保目录调整对创新药的持续倾斜，市场看好相关创新药及制药企业的医保准入与商保增量空间，作为相关企业之一的中国生物制药因此受到资金追捧。
中国生物制药(01177)今日盘中大涨5.19%，引起了市场的广泛关注。
消息面上，国家医保局近日公示了通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单，本次形式审查呈现申报品种数量提高、通过率大幅提升、申报品种以新药为主等特征，充分体现了医保目录调整对创新药的持续倾斜，市场看好相关创新药及制药企业的医保准入与商保增量空间，作为相关企业之一的中国生物制药因此受到资金追捧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.